Antihemophilic factor viii

Characteristics

Chromatographically purified liofilizirovannaya fraction of human plasma containing the factor VIII blood coagulability.

Of drugs

Drugs, the lack of complementary factors out VIII. Located in a natural combination with the protein factor VIII, Villebranda factor. Included in the process of blood clotting, was moving in protrombina trombin and education fibrinovogo Sgustka.posle in / in the wake of the immediate activation of factor VIII reduced gradually to 15% within 12 hours

Indications

Hemophilia A; Acquired deficiency factor VIII; Disease accompanied by the formation of antibodies to factor VIII.

Side-Effects

Tachycardia, arterial gipotenzia, smoking, allergic and immunopatologicakie reactions : pain in the back, nausea, urticaria, temperature increases, anaphylactic shock; Education antibodies to factor VIII.

Specific guidance

Drugs factor VIII can be stored for two years, 2-8 ^ C, but they can not be frozen.

Precautions

The numerical control before and during therapy : with a significant increase in HR slow speed infusions or no introduction.

Dosing and Administration

In / in, and at speeds of 2-3 mL / min. The mode set individually controlled activity factor out VIII. The joint, muscle and tissue artistic methods level of factor VIII increase to a range of 10 to 20% (treatment duration of not less than 2-3 days); Teeth extraction or small transactions, not less than 30% (5 days), gastrointestinal artistic methods, not less than 50% (10-14 days); Extensive surgical interventions or intracranial krovoislianiah at no less than 60% (2-3 weeks). Initial dose (IU) looks as the product of the desired increase in the content of factor VIII (%), for weight (kg), which supports the dose is half primary. To prevent prolonged bleeding with severe hemophilia A is 12-25 IU / kg every 2-3 days.

Directory → Gematotropona funds → Coagulants (including factors such as blood clotting), gemostatiki → Antihemophilic factor viii